Catalyst Pharmaceuticals Files 8-K

Ticker: CPRX · Form: 8-K · Filed: 2025-01-08T00:00:00.000Z

Sentiment: neutral

Topics: regulatory-filing, financial-statements

TL;DR

Catalyst Pharma filed a routine 8-K, mostly exhibits. No major news.

AI Summary

On January 8, 2025, Catalyst Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or other significant business updates detailed in the provided text.

Why It Matters

This filing indicates Catalyst Pharmaceuticals is up-to-date with its regulatory reporting requirements, which is standard practice for publicly traded companies.

Risk Assessment

Risk Level: low — The filing is a standard regulatory disclosure and does not contain information that suggests an immediate change in the company's risk profile.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Catalyst Pharmaceuticals, Inc.?

The primary purpose of this 8-K filing is to report financial statements and exhibits, as indicated by the filing's item information.

When was this 8-K report filed by Catalyst Pharmaceuticals, Inc.?

This 8-K report was filed on January 8, 2025.

In which state is Catalyst Pharmaceuticals, Inc. incorporated?

Catalyst Pharmaceuticals, Inc. is incorporated in Delaware.

What is the principal executive office address for Catalyst Pharmaceuticals, Inc.?

The principal executive office address is 355 Alhambra Circle Suite 801 Coral Gables, Florida 33134.

Does this filing report any specific material events or other significant business updates?

Based on the provided text, the filing primarily concerns financial statements and exhibits, and does not detail specific material events or other significant business updates.

From the Filing

0001193125-25-003549.txt : 20250108 0001193125-25-003549.hdr.sgml : 20250108 20250108164318 ACCESSION NUMBER: 0001193125-25-003549 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250108 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250108 DATE AS OF CHANGE: 20250108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 25519038 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 8-K 1 d890025d8k.htm 8-K 8-K NASDAQ false 0001369568 0001369568 2025-01-08 2025-01-08     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 8, 2025     CATALYST PHARMACEUTICALS, INC. (Exact Name Of Registrant As Specified In Its Charter)       Delaware   001-33057   76-0837053 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   355 Alhambra Circle Suite 801 Coral Gables , Florida   33134 (Address of principal executive offices)   (Zip Code) Registrant’s telephone number, including area code: (305) 420-3200 Not Applicable Former Name or Former address, if changed since last report     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of Each Class   Name of Exchange on Which Registered   Ticker Symbol Common Stock, par value $0.001 per share   NASDAQ Capital Market   CPRX Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events On January 8, 2025, the Company issued a press release announcing that it and its licensor, SERB S.A. (“SERB”) have entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (collectively “Teva”). This agreement resolves the patent litigation brought by the Company and SERB in response to Teva’s Abbreviated New Drug Application

View on Read The Filing